The Manufacturers Life Insurance Company Invests $10.62 Million in Medpace Holdings, Inc. $MEDP

The Manufacturers Life Insurance Company purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 20,043 shares of the company’s stock, valued at approximately $10,615,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. bought a new stake in Medpace during the 2nd quarter worth about $27,000. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new position in shares of Medpace in the 4th quarter valued at about $30,000. Jones Financial Companies Lllp acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the second quarter worth approximately $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total value of $16,814,999.46. Following the sale, the chief executive officer directly owned 561,195 shares in the company, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 133,821 shares of company stock worth $81,748,135 in the last three months. 20.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Mizuho raised their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Trading Down 1.8%

Shares of NASDAQ MEDP opened at $600.65 on Friday. The company has a fifty day moving average price of $565.33 and a 200 day moving average price of $494.55. The firm has a market cap of $16.77 billion, a PE ratio of 35.21, a PEG ratio of 2.68 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.